HER2+ 유방암

218개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved218 programs
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

trastuzumab (Herceptin, Taxanes combined with trastuzumab and pertuzumab.)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedHER2-positiveBreastCance+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （12weeks） (Toripalimab （12weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （18weeks） (Toripalimab （18weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

SHR-A1811 (Trastuzumab Rezetecan, Trastuzumab Rezetecan (SHR-A1811))

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

Zenocutuzumab (Zenocutuzumab)

Breast Cancer Metastatic · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Merus
Trials 1Status Active
AntibodyLimited DatastaleJules Bordet InstitutePhase 1

trastuzumab (Herceptin, Zr89-trastuzumab)

Breast Neoplasms; Secondary · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
ADCLimited DatastaleMabwell (Shanghai) Bioscience C…Phase 1

bulumtatug fuvedotin (bulumtatug fuvedotin)

Triple Negative Breast Cancer · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#antibody-drug-conjugate#Mabwell
Trials 1Status Recruiting

10 / 11 pages

← PreviousNext →